Alladapt Immunotherapeutics Presents Phase 1/2 Harmony Data Demonstrating Therapeutic Potential and Safety of ADP101 for the ...
– Results aligned with patient needs and clinical practice priorities – – Alladapt preparing for ADP101 Phase 3 study in 2024 – MENLO PARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics, Inc., a private, clinical-stage …